#Burkitt’s lymphoma

[pavankalnad]

Endoxan N 500 mg Injection is a prescription medication known as cytophosphane, and this medicine is classified as an alkylating agent. You can buy Endoxan N 500 mg Injection online at Buysm and get up to 75% off with home delivery. Check Endoxan N 500 mg Injection Price, Uses, Side Effects and Dosage.

[plunes-healthcare]

Burkitt Lymphoma Treatment

Explore Burkitt Lymphoma Treatment with Plunes HealthCare. Access information on treatment options and specialized care. Benefit from up to 50% off on consultations, access 1100+ hospitals, and calculate treatment costs. Call us at 7011311900 for personalized assistance.

[diamondthehypnohornydom]

First Post

Hello there, my bimbo suggested I should make a Tumblr account and post here so ill be using this to talk about plans I have for her, random horny fantasies, and stories about what I have already done to her. (she already follows me so she'll get to be surprised by stuff ive made her forget about)

Feel free to call me Diamond or Sir, whichever you would prefer. Master and Daddy are reserved for my Toy to use

About me:

I’m a 20 year old CIS man that has been into hypno for a few years but only got into the community about a year ago. I play a lot of video games.

Got diagnosed with Burkitt’s Lymphoma in 2023 but I completely won my battle after three rounds ending in August!

Any files i have are listed below the break

[justforbooks]

It did not seem like a good thing when a precious consignment of human tumour samples on its way from Kampala, Uganda, to Heathrow was diverted to Manchester. When the samples finally arrived at the Middlesex hospital in London, they were swimming in murky fluid in their vials as though they had been infected with bacteria.

But when the pathologist Anthony Epstein looked at the fluid under the microscope he saw no bacteria, just individual cells that had been shaken loose from the tumours. And that was just what he needed in order to search for elusive virus particles and test his hunch that they were causing cancer.

In the early 1960s Epstein, who has died aged 102, had heard a lecture by Denis Burkitt, an Irish surgeon working in Kampala, that described strange tumours (now known as Burkitt lymphoma) growing around the jaws of children in equatorial Africa.

Intriguingly, the geographical distribution of the condition seemed to depend on temperature and rainfall, suggesting a biological cause. Epstein, who had been working with viruses that cause cancer in chickens, immediately suspected a virus might be involved, perhaps in association with another tropical disease such as malaria.

Epstein began to collaborate with Burkitt, who supplied him with tumours from children he had treated. But Epstein’s efforts to grow pieces of tumour in the laboratory and isolate a virus had all been unsuccessful until the dissociated cells arrived.

With his graduate student Yvonne Barr, he then decided to look at cultures of these cells in an electron microscope, a powerful instrument that had only recently become available in his lab.

The very first image showed a tell-tale outline that looked like one of the family of herpes viruses. It turned out to be a previously undescribed member of that family, and was given the name Epstein-Barr virus. In 1964, Epstein, Barr and Epstein’s research assistant, Bert Achong, published the first evidence that cancer in humans could be caused by a virus – to be greeted by widespread scepticism even though they went on to demonstrate that EB virus caused tumours in monkeys.

Thanks to samples supplied by Epstein, in 1970 Werner and Gertrude Henle at the Children’s hospital in Philadelphia discovered that EB virus also caused glandular fever. That made it possible to design a test for antibodies to the virus in order to confirm a diagnosis. EB virus turned out to be very common, infecting most children in early life, though it usually causes glandular fever only in older teenagers and young adults. As well as causing Burkitt lymphoma in endemic areas in Africa and Papua New Guinea, it is also associated with a cancer of the nose and throat that is the most common cancer of men in south China, as well as cancers in people whose immune systems have been compromised, such as those infected with HIV.

More recent research suggests that EB virus might also be involved in some cases of multiple sclerosis, and that people who have previously had glandular fever are more susceptible to severe Covid-19.

After the discovery, Epstein and others devoted time and effort to trying to find out under what circumstances EB virus causes cancer. The relationship between the virus, other diseases, human genetics and cancer is complex, and it took decades before the medical community could accept the EB virus as a cause with confidence.

Not until 1997 did the International Agency for Research on Cancer class it as a Group 1 carcinogen, formally acknowledging its role in a variety of cancers.

The discovery of EB virus opened up a whole new field of research into cancer-causing viruses. It also raised the exciting possibility of preventing cancers through vaccination, an advance that has now been achieved in the case of human papilloma virus, which causes cervical cancer, and hepatitis B virus, which causes liver cancer.

By the time of his retirement in 1985, Epstein’s research group at the University of Bristol had developed a candidate vaccine that protected monkeys infected with EB virus against tumours, but neither it nor any other candidate has yet been successfully developed for human use.

Epstein was born in London, one of three children of Olga (nee Oppenheimer) and Mortimer Epstein. Mortimer was a writer and translator who edited The Statesman’s Yearbook for Macmillan from 1924 until his death in 1946. Olga was involved with charitable work in the Jewish community. Anthony attended St Paul’s school in west London, where the biology teacher Sidney Pask encouraged boys to go far beyond the syllabus and whose pupils also included Robert Winston and Jonathan Miller.

Epstein won a place to study medicine at Trinity College, Cambridge. He moved to Middlesex hospital medical school in wartime London to complete his training, before doing his national service in India with the Royal Army Medical Corps. He returned to work at the Middlesex hospital as assistant pathologist, conducting his own research. Thinking electron microscopy might be useful in his studies of cancer-causing viruses in chickens, he spent some time learning the new technique at the Rockefeller Institute in New York (now Rockefeller University). Not long afterwards he attended Burkitt’s lecture and began the serendipitous route to his discovery.

In 1968 he was appointed professor and head of the department of pathology at the University of Bristol, where he remained until his retirement. He moved to Oxford as a fellow of Wolfson College in 1986, becoming an honorary fellow in 2001.

An exemplary scientific good citizen, he served as foreign secretary and vice-president of the Royal Society, and sat on boards and councils for numerous national and international research organisations, including as a special representative of the director general of Unesco; he was also a patron of Humanists UK. Among his many prizes and honorary degrees, he received the international Gairdner award for biomedical research in 1988. He was appointed CBE in 1985 and knighted in 1991.

“It was a series of accidents, really,” he said of his discovery in a conversation with Burkitt they recorded for Oxford Brookes University’s oral history archive in 1991. “Lucky quirks.” Burkitt immediately responded with Louis Pasteur’s aphorism: “Chance favours the prepared mind.”

Epstein was a deeply cultured man who retained a lively interest in many subjects – particularly oriental rugs, Tibet and amphibians – until the end of his life.

He is survived by his partner, Kate Ward, by his children Susan, Simon and Michael, from his marriage to Lisbeth Knight, from whom he was separated in 1965, and who died in 2015, and by two grandchildren and two great-grandchildren.

🔔Michael Anthony Epstein, pathologist, born 18 May 1921; died 6 February 2024

Daily inspiration. Discover more photos at Just for Books…?

[atelier-dayz]

mantle cell lymphoma -> t(11;14)

(extranodal) marginal zone lymphoma (GI MALT) -> t(11;18)

follicular lymphoma -> t(14;18)

Burkitt lymphoma -> t(8;14)

I just wanted to complain about this, because as someone who gets numbers mixed up sometimes, remembering these translocations is A PAIN IN THE ASS UGHHHH

┻━┻︵ヽ(`Д´)ﾉ︵ ┻━┻

[stevecrom]

Autobiography

Growing up in a family of mechanics teaches you one thing. How does something work. From a young age I was always intrigued with transportation. If it had wheels and a motor I was interested. It all started with my first car. I couldn't afford an expensive car working at McDonalds and being in High School. I knew I would have to work on it myself. I'm very fortunate that our School had a Mechanics class and a paint booth. My instructor Mr. Anderson really helped me decide in the end how my life would change once I graduated. The school had a work experience program which I enrolled in. At the end of my work experience I was hired at the local body shop. 3 months later I was signed up on my Autobody Technician Apprenticeship. This would of been 1990 just for relevance. Now, I have 3 red seals in Automotive Collision and Refinishing. I also worked at the same shop I started at for 20 years. I then opened my own shop for 10 years restoring and building muscle cars, hot rods, and motorcycles. Many of my paint jobs have graced magazine feature articles. Then when you feel you are on top of the world. Something happens!!!!!!!!!!

I get sick. Nothing like a health scare to change your direction or maybe the way you now view the world. Stage 4 Cancer Burkitt's Lymphoma. I beat it 7 years Cancer free at the moment and feeling blessed with every day I walk this earth. I returned to the shop I started at for 5 years after my Cancer. I'm now instructing Collision and Auto Refinishing at Vancouver Community College.

[stevenwilliam12]

Epstein-Barr Virus (EBV) Vaccines: Emerging Market and Market Forecast to 2034

Introduction

Epstein-Barr Virus (EBV) is one of the most common human viruses, affecting nearly 90% of the global population at some point in their lives. While EBV infections are typically mild and self-limiting, the virus has been linked to a range of serious conditions, including various cancers (such as Burkitt lymphoma, nasopharyngeal carcinoma, and Hodgkin’s lymphoma), autoimmune diseases, and chronic conditions like infectious mononucleosis. The Epstein-Barr virus (EBV) market is evolving rapidly, with ongoing research into vaccines, antiviral therapies, and diagnostics. This article explores the EBV market, its epidemiology, and future market forecasts through 2034.

Epstein Barr Virus (EBV) Market Insight

The Epstein-Barr virus (EBV) market is shaped by the growing awareness of EBV-related diseases, as well as the increasing recognition of its role in several cancers and autoimmune disorders. While the majority of EBV infections are asymptomatic, a subset of individuals develop serious conditions linked to the virus. This has led to an increased demand for diagnostic tests, therapeutic interventions, and vaccines aimed at preventing or treating EBV-related diseases.

Currently, the Epstein-Barr virus (EBV) market is focused on developing effective antiviral drugs, as well as preventive vaccines. Although no vaccines or antiviral treatments are yet universally approved for EBV, several pharmaceutical companies and research institutions are actively working on solutions. Epstein-Barr virus (EBV) market research indicates that there is a growing pipeline of therapies and vaccines in clinical development, with some showing promise in early trials. The market is also benefiting from increased funding and collaborative efforts to address EBV-related conditions.

Epidemiology of Epstein Barr Virus (EBV)

The epidemiology of EBV is characterized by its high global prevalence. Almost everyone is exposed to EBV in childhood or adolescence, and the majority of cases are asymptomatic. However, for some individuals, EBV infection can lead to a variety of health problems, including:

Cancers: EBV is implicated in several types of cancer, including Burkitt lymphoma, nasopharyngeal carcinoma, and some forms of Hodgkin lymphoma. The increasing incidence of these EBV-associated cancers, particularly in certain regions of the world, is contributing to the growth of the EBV market.

Autoimmune Disorders: Conditions like multiple sclerosis, lupus, and rheumatoid arthritis have been linked to EBV infection, further driving the demand for diagnostic tools and therapeutic treatments targeting the virus.

Chronic Diseases: Chronic conditions such as chronic fatigue syndrome and EBV-related mononucleosis are gaining recognition, which has led to increased research into long-term management and potential treatments.

Despite its high prevalence, EBV infection often goes unnoticed, and many patients remain undiagnosed until they develop severe symptoms or complications. This presents a significant opportunity for early detection, treatment, and preventative measures within the Epstein-Barr virus (EBV) market.

Market Forecast – 2034

The Epstein-Barr virus (EBV) market is expected to experience substantial growth through 2034. Key drivers of this growth include:

Vaccine Development: The introduction of effective EBV vaccines would drastically reduce the incidence of EBV-related cancers and autoimmune diseases, creating significant demand in the market.

Advancements in Antiviral Therapies: Ongoing research into antiviral treatments for EBV is promising, with potential breakthroughs in drug development that could offer more effective treatments for EBV-related conditions.

Diagnostics: As the demand for early diagnosis of EBV-related conditions increases, the market for diagnostic tools will also expand. More sensitive and specific testing methods are expected to improve detection rates, particularly for cancers and autoimmune diseases linked to EBV.

Rising Incidence of EBV-Related Diseases: The increasing recognition of EBV’s role in various chronic and life-threatening diseases will boost demand for both diagnostic and therapeutic interventions.

Overall, the Epstein-Barr virus (EBV) market is poised for continued growth, with promising advancements in vaccine development, antiviral therapies, and diagnostics driving future market dynamics.

Conclusion

The Epstein Barr virus (EBV) market is undergoing a significant transformation, driven by advances in research and development, increased awareness of EBV-related diseases, and growing demand for diagnostic and therapeutic solutions. As the incidence of EBV-associated cancers and autoimmune disorders continues to rise, the market will see a surge in demand for effective vaccines, antiviral drugs, and diagnostic tools. The Epstein-Barr virus (EBV) market research points to a promising future, with substantial growth expected through 2034. This provides an opportunity for both existing players and new entrants to innovate and meet the unmet medical needs associated with EBV infections.

Latest Reports

neuroprosthetics market | non-radiographic axial spondyloarthritis market | non-st segment elevation acute coronary syndromes market | noonan syndrome market | osteogenesis imperfcta market | persistent epithelial defects post-transplant lymphoproliferative disease market | postsurgical pain market | primary mediastinal large b-cell lymphoma market | pyruvate kinase deficiency market | radiofrequency ablation devices market | recurrent blood clots market | refractory epilepsy market | retinitis pigmentosa market | retinopathy of prematurity market | rosacea market | spinal stenosis market | subarachnoid hemorrhage market | surgical bleeding market | typhoid fever market | uveal neoplasms market | ventricular hypertrophy market | vernal keratoconjunctivitis market | vertebral body replacement systems market 

[isaiah4031kjv]

Fiber Man (Psalm 1:2-3)

This slideshow requires JavaScript. Dr. Denis Burkitt achieved fame for discovering the cause and cure of a disease named after him – Burkitt lymphoma. He also received widespread acclaim for demonstrating the benefits of a fiber-rich diet, which earned him the amusing nickname “Fiber Man.” What many people don’t know, however, is that Dr. Burkitt was not merely a great medical pioneer; he was a…

[nathfiset]

What is Non-Hodgkin’s Lymphoma and how can FDA approved cord blood banking help?

I am ready to enroll in cord blood banking NOW and get my special discount!

By clicking on either buttons, you are agreeing to our TOS and disclaimers and will be redirected to an affiliate cord blood banking provider. We might get financial compensation if you sign up with them through our affiliate links. Unlock your special discounts by adding your promo code.CORD300 in the coupon field to get $300 OFF cord blood and tissue banking. OR cord200 to get $200 OFF if you are getting cord blood banking only. I want more information on cord blood banking

 Non-Hodgkin’s Lymphoma (NHL) is a type of cancer that affects the lymphatic system, which is a crucial part of the body's immune system. It is a heterogeneous group of lymphoproliferative malignancies, with over 90 different subtypes identified. According to the American Cancer Society, NHL accounts for about 4% of all cancers in the United States, making it one of the most prevalent types of cancer. The exact cause of NHL is still unknown, but research suggests that certain risk factors, such as age, weakened immune system, and exposure to certain chemicals, may increase the likelihood of developing the disease. In recent years, the use of cord blood banking has been gaining attention as a potential treatment option for NHL. Cord blood, collected from the umbilical cord after a baby is born, contains valuable stem cells that can be used in transplant procedures to treat various diseases, including NHL. In this article, we will delve into the details of Non-Hodgkin’s Lymphoma, the current treatment options available, and how FDA-approved cord blood banking can potentially revolutionize the treatment of this disease.

Understanding Non-Hodgkin's Lymphoma: Causes and Symptoms

Non-Hodgkin's lymphoma is a type of cancer that affects the lymphatic system, which is a part of the body's immune system. While the exact cause of this disease is not fully understood, certain risk factors have been identified. These include a weakened immune system, exposure to certain chemicals or radiation, certain infections such as Epstein-Barr virus and HIV, as well as genetic factors. It is important to be aware of the common symptoms of Non-Hodgkin's lymphoma, which can include swollen lymph nodes, fever, night sweats, unexplained weight loss, fatigue, and persistent coughing or trouble breathing. Early detection and diagnosis of Non-Hodgkin's lymphoma is crucial for effective treatment and improved outcomes.

Types of Non-Hodgkin's Lymphoma

Non-Hodgkin's lymphoma is a complex disease with various subtypes, each characterized by distinct characteristics and behaviors. The most common types include diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma. DLBCL is the most prevalent subtype, accounting for approximately 30% of cases, and it typically presents as rapidly growing tumors. Follicular lymphoma, on the other hand, is usually slower growing and tends to be indolent. Mantle cell lymphoma is a more aggressive subtype, often affecting older individuals, while Burkitt lymphoma is a rare but highly aggressive form primarily found in children and young adults. Accurate diagnosis and understanding the specific type of Non-Hodgkin's lymphoma are essential for developing tailored treatment plans and improving patient outcomes.

Importance of Early Detection and Treatment

Early detection and timely treatment are crucial when it comes to Non-Hodgkin's lymphoma. The importance of early detection lies in the fact that this disease can progress rapidly if left untreated. By identifying the signs and symptoms at an early stage, healthcare professionals can initiate appropriate diagnostic tests and interventions promptly. This allows for a more targeted and effective treatment plan, potentially increasing the chances of successful outcomes and improving the overall prognosis for patients. Early detection also provides an opportunity to address the disease before it spreads to other parts of the body, minimizing the need for more aggressive treatment approaches. It is important for individuals to be aware of the potential risk factors and to seek medical attention if they notice any concerning symptoms, as this can significantly impact the management and potential success in overcoming Non-Hodgkin's lymphoma.

Role of FDA in Regulating Cord Blood Banking

The role of the FDA in regulating cord blood banking is instrumental in ensuring the safety and efficacy of this medical practice. Cord blood banking involves the collection and storage of stem cells from the umbilical cord after childbirth, which can subsequently be used for potential medical treatments. The FDA plays a crucial role in overseeing the quality and proper handling of cord blood units, as well as the screening and testing of donated cord blood for infectious diseases. By establishing regulations and standards, the FDA helps to safeguard the integrity of cord blood banks and ensures that the collected stem cells are of high quality and safe for potential therapeutic use. This regulatory oversight instills confidence in both healthcare professionals and patients utilizing cord blood banking services, as they can trust that FDA-approved banks adhere to stringent quality and safety measures.

What is Cord Blood Banking?

Cord blood banking refers to the process of collecting, processing, and storing stem cells found in the umbilical cord and placenta after childbirth. These stem cells have the potential to develop into various types of cells, including blood cells, and can be used in the treatment of a range of diseases and conditions. After a baby is born, the umbilical cord is clamped and cut, and the remaining blood in the cord is collected in a special bag. This blood is rich in hematopoietic stem cells, which have the ability to regenerate and replace damaged or diseased cells in the body. Cord blood banking offers a unique opportunity for families to bank these valuable stem cells for potential future use, providing a source of cells that may be a genetic match for the individual or a family member. By preserving cord blood, families can have access to a potentially life-saving resource in the event of certain diseases or conditions.

Benefits of Cord Blood Banking

Preservation of cord blood through banking offers numerous benefits to families and individuals. Firstly, it provides a valuable source of stem cells that can be utilized in the treatment of various diseases and conditions. These stem cells have the potential to regenerate and replace damaged or diseased cells, offering a potential cure or significant improvement for patients. Additionally, cord blood banking ensures a genetic match for the individual or their family members, increasing the likelihood of successful transplantation and reducing the risk of rejection. Moreover, cord blood banking is a non-invasive and painless procedure that can be easily performed after childbirth, posing no harm to the mother or baby. With the advancement of FDA-approved cord blood banking, families can have peace of mind knowing that they have a potentially life-saving resource readily available if the need arises.

Process of Cord Blood Collection

During the process of cord blood collection, healthcare professionals follow a precise set of steps to ensure the safe and efficient retrieval of this valuable resource. After the baby is delivered, the umbilical cord is clamped and cut. Then, using a sterile collection kit provided by the cord blood bank, the healthcare provider inserts a needle into the umbilical vein and allows the blood to flow into a collection bag or vial. The collection process is completely painless and does not pose any risk or discomfort to the mother or newborn. The collected cord blood is then carefully labeled and transported to a laboratory for processing and storage. Here, it undergoes a series of tests and quality checks to ensure its viability and suitability for future use. The process of cord blood collection is a simple yet crucial step in harnessing the potential of these stem cells to aid in the treatment of various diseases and conditions.

FDA Approved Cord Blood Banks

FDA approved cord blood banks play a vital role in ensuring the safety and quality of cord blood units for potential therapeutic use. These banks adhere to strict regulations and guidelines set forth by the U.S. Food and Drug Administration (FDA) to ensure that the cord blood units stored within their facilities meet the highest standards. The FDA conducts thorough inspections and assessments to evaluate the collection, testing, processing, and storage procedures of these banks, ensuring that they comply with the necessary protocols. By choosing an FDA approved cord blood bank, individuals can have confidence in the quality and efficacy of the cord blood units, providing them with peace of mind for potential future treatments.

How Cord Blood Can Treat Non-Hodgkin's Lymphoma

Non-Hodgkin's lymphoma, a type of cancer that affects the lymphatic system, can be a challenging condition to treat. However, recent advancements in medical research have shown promising results in using cord blood as a potential treatment option. Cord blood, rich in hematopoietic stem cells, has the ability to differentiate into various types of blood cells, including immune cells. These cells can be harnessed to target and destroy cancerous cells in patients with non-Hodgkin's lymphoma. By utilizing the unique properties of cord blood, medical professionals can potentially enhance the body's ability to fight this aggressive form of cancer. Ongoing clinical trials and research continue to explore the full potential and effectiveness of cord blood in treating non-Hodgkin's lymphoma, offering hope for improved treatment outcomes for patients in the future.

The Future of Cord Blood Banking and Non-Hodgkin's Lymphoma Treatment

The future of cord blood banking and its potential role in non-Hodgkin's lymphoma treatment holds great promise. As medical advancements continue to unfold, the utilization of cord blood and its valuable stem cells may become a mainstream therapeutic approach for patients with this type of cancer. The development of advanced techniques for isolating and expanding the hematopoietic stem cells present in cord blood, along with the continuous improvement of transplantation protocols, may significantly improve the outcomes for individuals battling non-Hodgkin's lymphoma. Additionally, ongoing research exploring the use of gene editing technologies and cellular therapies may further enhance the effectiveness and precision of cord blood-based treatments. The establishment of FDA-approved cord blood banks ensures the availability of these valuable resources and provides a foundation for future advancements in the field. With continued research and innovation, the integration of cord blood banking into non-Hodgkin's lymphoma treatment protocols has the potential to revolutionize the way we approach and manage this challenging disease.In conclusion, Non-Hodgkin's Lymphoma is a serious and potentially life-threatening disease that affects many individuals each year. However, with advancements in medical treatments and the use of FDA approved cord blood banking, there is hope for those diagnosed with this condition. By preserving and storing cord blood stem cells, patients have the potential to access life-saving treatments and improve their chances of remission. It is important for individuals to educate themselves on this disease and the options available to them in order to make the best decisions for their health and well-being.

FAQ

What is Non-Hodgkin’s Lymphoma and how does it differ from Hodgkin’s Lymphoma?Non-Hodgkin’s Lymphoma is a type of cancer that originates in the lymphatic system, affecting white blood cells called lymphocytes. It differs from Hodgkin’s Lymphoma in terms of the specific type of lymphocytes involved, their behavior, and how they spread in the body. Non-Hodgkin’s Lymphoma is more common than Hodgkin’s Lymphoma and has a wider range of subtypes, making it more diverse in terms of presentation and treatment options. Additionally, the presence of Reed-Sternberg cells, a type of abnormal cell, is a defining characteristic of Hodgkin’s Lymphoma, distinguishing it from Non-Hodgkin’s Lymphoma.How can FDA approved cord blood banking be used in the treatment of Non-Hodgkin’s Lymphoma?FDA approved cord blood banking can be used in the treatment of Non-Hodgkin’s Lymphoma by providing a source of hematopoietic stem cells for transplantation. These stem cells can be used to restore the patient's immune system after high-dose chemotherapy or radiation therapy, which are common treatments for Non-Hodgkin’s Lymphoma. Cord blood banking ensures that these stem cells are readily available for transplantation when needed, offering a potentially life-saving treatment option for patients with this type of cancer.What are the benefits of using cord blood stem cells in the treatment of Non-Hodgkin’s Lymphoma compared to other treatment options?Cord blood stem cells offer several advantages in treating Non-Hodgkin's Lymphoma, including reduced risk of graft-versus-host disease, faster engraftment, lower rates of infection, and potentially higher success rates due to their immunological naivety. This form of treatment also allows for greater compatibility with a wider range of donors, offering more options for patients in need of a stem cell transplant. Overall, cord blood stem cells can provide a more effective and safer treatment option for Non-Hodgkin's Lymphoma compared to other alternatives.Are there any risks or limitations associated with using cord blood banking for Non-Hodgkin’s Lymphoma treatment?There are potential limitations and risks associated with using cord blood banking for Non-Hodgkin’s Lymphoma treatment, including the possibility of insufficient cell dose for transplantation, lack of HLA-matching leading to graft failure or complications, and the risk of disease relapse post-transplantation. It is important to consult with healthcare professionals to weigh the benefits and risks before deciding to pursue cord blood banking for Non-Hodgkin’s Lymphoma treatment.How does the FDA approval process for cord blood banking ensure the safety and efficacy of treatments for Non-Hodgkin’s Lymphoma?The FDA approval process for cord blood banking ensures the safety and efficacy of treatments for Non-Hodgkin’s Lymphoma by thoroughly evaluating the quality and effectiveness of cord blood units collected and stored for transplantation. This rigorous process involves assessing donor screening, collection methods, processing techniques, and storage conditions to ensure that the cord blood units meet the necessary standards for transplantation. By regulating these aspects of cord blood banking, the FDA helps to ensure that patients with Non-Hodgkin’s Lymphoma receive safe and effective treatments using cord blood stem cells.  Read the full article

[popgenpapers]

Incorporation of Epstein-Barr viral variation implicates significance of LMP1 in survival prediction and prognostic subgrouping in Burkitt lymphoma

http://dlvr.it/T6W6zV

[storelatina]

Burkitt's lymphoma: what it is, symptoms, causes and treatment - https://storelatina.com/?p=96515

[1989soundwaveblog]

HEALING BURKITT LYMPHOMA: THE ROLE OF RIFE FREQUENCY AND BINAURAL BEATS ...

[shahananasrin-blog]

[ad_1] Newswise — MIAMI, FLORIDA (SEPT. 14, 2023) – Some patients with aggressive lymphomas face a rare but clinically challenging prognosis when their cancer spreads to the central nervous system (CNS) or relapses there.Known as secondary CNS lymphoma or SCNSL, it can occur during or after initial chemotherapy treatment and is often associated with disappointing outcomes. Although it only occurs in about 4% to 6% of patients with the most common lymphoma, large-B cell lymphoma, its incidence jumps to almost 20% of patients with Burkitt lymphoma, a rarer and highly aggressive form of the disease.In a newly published paper in Blood, Journal of the American Society of Hematology, researchers from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations clarify current treatment approaches  in the management of patients with SCNSL caused by aggressive lymphoma.“Secondary CNS lymphoma is a challenging condition associated with shorter survival rates in a significant number of patients,” said Juan Alderuccio, MD, a Sylvester hematologist and  lymphoma specialist, and the manuscript’s corresponding author.He and his research colleagues noted that patients with SCNSL were largely excluded from clinical trials testing novel agents in aggressive lymphoma with current recommendations originating from retrospective and single-arm studies. However, results reported from regimens used in the international MARIETTA study as well as other immunochemotherapy regimens followed by consolidation with autologous stem cell transplant show improved outcomes in those with SCNSL at presentation or isolated CNS relapse.“For patients experiencing accompanying systemic with CNS lymphoma relapse, their prognosis can be especially bleak.”  “However, there may be hope on the horizon for these patients with development of potentially effective therapies such as antiCD19 CAR T-cell therapy,” Alderuccio said, explaining that this approach has been associated with encouraging preliminary efficacy. However, the duration of response is presently unknown.He pointed out that CAR T-cell therapy preliminarily demonstrated very good outcomes in treating large B-cell lymphoma with CNS involvement without causing higher neurotoxicity, a frequent complication of this therapy.“At Sylvester, we are currently evaluating the genomic landscape and role of circulatory biomarkers to better risk-stratify and track treatment response at a molecular level in patients with SCNSL,” Alderuccio concluded. “Our lymphoma group is also developing clinical trials in this difficult-to-treat population to improve outcomes.”# # #DOI: 10.1182/blood.2023020168AuthorsThe paper was written in collaboration with investigators from the University College London Hospitals and Dana-Farber Cancer Institute, Harvard Medical School.Competing InterestsThe authors disclosed several potential conflicts of interest that are included in the paper.FundingNo funding was provided for this manuscript. window.fbAsyncInit = function () FB.init( appId: '890013651056181', xfbml: true, version: 'v2.2' ); ; (function (d, s, id) var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) return; js = d.createElement(s); js.id = id; js.src = " fjs.parentNode.insertBefore(js, fjs); (document, 'script', 'facebook-jssdk')); [ad_2]

[thebrokencrescent-blog]

📆 Aug 2020 📰 'Mono' virus turns on cancer-related genes. Here's how. 🗞 Live Science

A type of herpes virus, one that causes mono, can in rare cases raise the risk of developing certain types of cancer. And now researchers know how: The Epstein-Barr virus (EBV) can directly latch onto bundles of genetic material in infected cells, and switch "on" nearby genes that turn healthy cells cancerous, according to a new study in human cells.

Not all people who become infected with EBV go on to develop cancer; but in rare instances, the virus can raise people's risk of developing nasopharyngeal cancer, Burkitt's lymphoma and certain stomach cancers, according to the American Cancer Society. While more than 90% of people catch the virus worldwide, only about 1.5% of cancer cases are linked to the infection, according to a 2019 report in the journal Annual Review of Pathology. Other viruses that drive cancer growth, such as hepatitis B and human papillomavirus (HPV), do so by worming their way into the genomes of their infected host — but EBV takes a different approach, researchers just found.

Understanding this process could allow scientists to develop drugs and gene therapies to undo the virus's harmful modifications, Rona Scott, an associate professor of microbiology and immunology at Louisiana State University Health Shreveport, who was not involved in the study, told Live Science in an email.

In addition, "identifying footprints [or telltale marks] of EBV infection in cancer may help us determine if EBV, which infects over 95% of adults worldwide, contributes to other cancers not yet associated with this virus," she said.

While some of the details remain fuzzy, "the link between EBV and certain types of cancer has been known for many years," Tan said. For example, the virus has been linked to about 8% to 10% of stomach cancers, which collectively stand as the third leading cause of cancer death globally, according to a statement from Duke-NUS Medical School.

Past research explained one way EBV fuels cancer: The virus triggers chemical reactions that stick molecular tags known as methyl groups onto genes, switching them "on" or "off," according to a 2007 report in the journal Cancer Science. One theory was that these so-called epigenetic modifications, meaning modifications "on top of" the genome, disabled genes that would normally suppress tumor growth.

But Tan wondered whether EBV was also changing the 3D structure of the host genome in ways that up the risk of cancer.

"We were definitely very surprised by the results," as we did not expect the viral genome to directly participate in rewiring the host cell, and controlling which proteins it builds, Tan said.

Even when the authors removed EBV from infected cells, the structural changes the virus made to host DNA stayed put. The finding supports prior evidence that EBV may contribute to cancer in a "hit-and-run" manner, meaning that even if you eliminate the virus itself, the cell's DNA remains altered and continues to drive tumor growth, Scott said.

In addition, "identifying footprints [or telltale marks] of EBV infection in cancer may help us determine if EBV, which infects over 95% of adults worldwide, contributes to other cancers not yet associated with this virus," she said.